Literature DB >> 26878661

Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy.

N Kawashima1, Y Inamoto2, T Sato1, M Nakashima1, Y Kagaya1, K Watakabe1, A Seto1, N Fukushima1, S Kurahashi1, Y Ozawa1, K Miyamura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26878661     DOI： 10.1038/bmt.2016.15

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  TBI and melphalan followed by allogeneic hematopoietic SCT in children with advanced hematological malignancies.

Authors:  J Inagaki; Y Nagatoshi; M Sakiyama; Y Nomura; H Teranishi; T Sasaki; J Okamura
Journal:  Bone Marrow Transplant       Date:  2010-11-01       Impact factor: 5.483

2.  A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation.

Authors:  M Murata; T Nishida; M Haneda; T Kanie; H Taji; H Iida; R Suzuki; M Hamaguchi; S Minami; Y Kodera
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

Review 3.  Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?

Authors:  K W Song; J Lipton
Journal:  Bone Marrow Transplant       Date:  2005-08       Impact factor: 5.483

4.  Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.

Authors:  G Helenglass; R L Powles; T J McElwain; A Lakhani; S Milan; M Gore; A Nandi; A Zuiable; T Perren; G Forgeson
Journal:  Bone Marrow Transplant       Date:  1988-01       Impact factor: 5.483

5.  Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  Alois Gratwohl; Ronald Brand; Jane Apperley; Charles Crawley; Tapani Ruutu; Paolo Corradini; Enric Carreras; Agnes Devergie; Cesare Guglielmi; Hans-Jochen Kolb; Dietger Niederwieser
Journal:  Haematologica       Date:  2006-03-01       Impact factor: 9.941

6.  Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation.

Authors:  Eric J Chow; K Scott Baker; Stephanie J Lee; Mary E D Flowers; Kara L Cushing-Haugen; Yoshihiro Inamoto; Nandita Khera; Wendy M Leisenring; Karen L Syrjala; Paul J Martin
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

7.  Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.

Authors:  R Martino; L de Wreede; M Fiocco; A van Biezen; P A von dem Borne; R-M Hamladji; L Volin; M Bornhäuser; M Robin; V Rocha; T de Witte; N Kröger; M Mohty
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

8.  Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.

Authors:  J E Anderson; F R Appelbaum; G Schoch; T Gooley; C Anasetti; W I Bensinger; E Bryant; C D Buckner; T Chauncey; R A Clift
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

9.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

Authors:  Edward A Copelan; Betty K Hamilton; Belinda Avalos; Kwang Woo Ahn; Brian J Bolwell; Xiaochun Zhu; Mahmoud Aljurf; Koen van Besien; Christopher Bredeson; Jean-Yves Cahn; Luciano J Costa; Marcos de Lima; Robert Peter Gale; Gregory A Hale; Joerg Halter; Mehdi Hamadani; Yoshihiro Inamoto; Rammurti T Kamble; Mark R Litzow; Alison W Loren; David I Marks; Eduardo Olavarria; Vivek Roy; Mitchell Sabloff; Bipin N Savani; Matthew Seftel; Harry C Schouten; Celalettin Ustun; Edmund K Waller; Daniel J Weisdorf; Baldeep Wirk; Mary M Horowitz; Mukta Arora; Jeff Szer; Jorge Cortes; Matt E Kalaycio; Richard T Maziarz; Wael Saber
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

10.  Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.

Authors:  Yachiyo Kuwatsuka; Koichi Miyamura; Ritsuro Suzuki; Masaharu Kasai; Atsuo Maruta; Hiroyasu Ogawa; Ryuji Tanosaki; Satoshi Takahashi; Kyuhei Koda; Kazuhiro Yago; Yoshiko Atsuta; Takashi Yoshida; Hisashi Sakamaki; Yoshihisa Kodera
Journal:  Blood       Date:  2009-01-06       Impact factor: 22.113
View more
  1 in total

1.  Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia.

Authors:  R Zhang; W Shi; H-F Wang; Y You; Z-D Zhong; W-M Li; C Zhang; X Lu; Y-D Wang; P Zheng; J Fang; M Hong; Q-L Wu; L-H Xia
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.